Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

VM Oncology

Status and phase

Enrolling

Phase 1

Conditions

Breast Cancer

Adenoid Cystic Carcinoma

Uterine Cancer

Esophageal Cancer

Lung Cancer

Ovarian Cancer

Any Solid Tumors Progressed After a Prior Immunotherapy

Non-Small Cell Lung Cancer

Thymoma

Head and Neck Carcinoma

Sarcoma

Bladder Cancer

Olfactory Neuroblastoma

Appendiceal Cancer

Mesothelioma

Thymic Carcinoma

Cervical Cancer

Pancreatic Cancer

Treatments

Drug: VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)

Study type

Interventional

Funder types

Industry

Identifiers

NCT03556228

VMO-01C

Details and patient eligibility

About

This is a multicenter, open-label, Phase 1 study of orally administered VMD-928 in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists

Full description

This is an open-label, Phase I, FTIH, multiple-dose, dose-escalation and cohort expansion multi-center study conducted in three parts to identify a safe and pharmacologically active dose and regimen for VMD-928 monotherapy, which can be implemented in Phase 2 studies (the RP2D). The regimen will be identified using an adaptive design, multiple-ascending dose study in cancer patients. To conserve patients in the lower dose cohorts, dose escalation will begin with an accelerated titration scheme. A second part of the study will assess antitumor activity at the RP2D. The third part of the study will collect tumor samples before and after treatment to assess biological activity.

Enrollment

82 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

Histologically or cytologically confirmed diagnosis of any type of solid tumor malignancy or lymphoma that is not responsive to standard therapies or had progressed following standard therapy and for which there is no approved or curative therapy. Additionally, patients must not be candidates for or have exhausted regimens known to provide clinical benefit, including hematopoietic stem cell transplantation in lymphoma patients if they are deemed transplant eligible.
ECOG score of 0 or 1.
Able to swallow and retain oral medication.
Adequate organ system function.
Subjects must either have available archival tumor tissue samples, or consent to tumor tissue sampling prior to the first dose, that is sufficient for IHC analysis of TrkA expression, except with prior documented NTRK+.
Subjects must have a tumor:

(i). with TrkA protein overexpression (TrkA+) in the validated TrkA IHC assay, OR (ii). with documented NTRK1 gene fusion (NTRK1+) including a tumor which has progressed due to NTRK1 mutation after treatment of a pan-Trk inhibitor (e.g. larotrectinib or entrectinib)
Adequate organ system function as defined as follows:
1. Absolute neutrophil count ≥1.5x10^9/L
2. Hemoglobin ≥9g/dL
3. Platelets ≥100x10^9/L
4. PT/INR, PTT ≤1.5xULN
5. Total bilirubin ≤1.5x ULN
6. AST, ALT ≤2.5xULN
7. Creatinine ≤1.2xULN for age, weight
8. Calculated creatinine clearance or 24h urine creatinine clearance ≥60mL/min

Key Exclusion Criteria:

Received chemotherapy having delayed toxicity within the last 14 days (six weeks for prior nitrosourea or mitomycin C).
Received anticancer therapy with radiation, immunotherapy, and a biologic, surgery and/or tumor embolization within the past 2 weeks.
Received an investigational anticancer drug within 14 days or 5 half-lives of the investigational agent, whichever is longer, prior to the first dose of VMD-928. Any exceptions to the above must be approved by the Sponsor Medical Monitor.
Unresolved toxicity from previous anticancer therapy &amp;amp;gt; CTCAE Grade 1 (except alopecia or anemia) unless agreed to by both the Sponsor Medical Monitor and the Investigator.
Negative result on TrkA immunohistochemistry (IHC) assay (if enrolled in dose expansion cohorts).
Known active infections including HIV disease.
Patients with a history of chronic viral hepatitis (HBV/HCV), even if treated, or a history of cirrhotic liver secondary to any etiology (i.e. alcoholism, non-alcoholic steatohepatitis).
Currently pregnant, nursing, or planning to become pregnant during the course of the study.
QTcF interval ≥ 480 msec.
Class II, III, or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system.
Acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting within the past 24 weeks.
Unstable or uncompensated respiratory, hepatic, renal, or cardiac disease that would compromise the patient's safety or interfere with assessment of the drug.
Psychological, familial, sociological, geographical, or other concurrent conditions that would interfere with safety evaluation, limit the patient's ability to follow the procedures in the protocol or otherwise jeopardize compliance with the protocol. Patients with uncontrolled major depression, bipolar disorder, or severe anxiety disorder are excluded.
Known immediate or delayed hypersensitivity reaction or idiosyncrasy to the study drug, or excipients.
Patient has had or is currently having other malignant tumors within 3 years.
Patients have multiple factors that affect their oral medication.
Patients have long-term unhealed wounds or fractures.
Patients have uncontrolled pleural effusion, pericardial effusion, or ascites that still require repeated drainage.
Patients are taking the following drugs and can't stop them during the study:
- Tylenol or medicine containing acetaminophen (paracetamol).
- Strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers.